Drugs / Trimetazidine
Trimetazidine
also known as
TMZ · Trimetazidine hydrochloride · Dilatan · metacardia · NSC-759317 · Trimetazidina · Trimetazidine di-hcl · Trimetazidine dihydrochloride · +5 more
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03737448 | Nov 2018 → Jun 2021 | liver disorder | Martin Pharmaceuticals | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07794475 | Aug 2026 → Feb 2027 expected | neuropathy, painful | Sara Refaat Azab Metry | Recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07836699 | Sep 2026 → Aug 2027 expected | — | Fábio Fernandes | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06140953 | Dec 2023 → Jun 2024 | metabolic dysfunction-associated steatotic liver disease | October 6 University | Completed | No outcome recorded |
| Phase 2 | NCT05556005 | Sep 2022 → Sep 2023 | cardiomyopathy, type 2 diabetes mellitus | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT05147194 | Jan 2022 → Dec 2023 | diabetic kidney disease | Tongji Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04788745 | Jun 2021 → May 2023 | amyotrophic lateral sclerosis | The University of Queensland | Completed | No outcome recorded |
| Phase 2 | NCT04760821 | Dec 2020 → Apr 2021 | COVID-19, acute respiratory distress syndrome | Ministry of Health, Brazil | Unknown | No outcome recorded |
| Phase 2 | NCT03603249 | Jul 2018 → Apr 2019 | platelet disorder, undefined | The University of The West Indies | Completed | No outcome recorded |
| Phase 2 | NCT02102672 | Mar 2014 → Dec 2016 | pulmonary arterial hypertension | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT04939857 | Jun 2021 → Jul 2022 | poisoning | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03273387 | Sep 2017 → Nov 2018 | pulmonary arterial hypertension | Indonesia University | Completed | Met primary |
| Phase 34 trials | ||||||
| Phase 3 | NCT04980716 | Jun 2021 → Jan 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT03715582 | Oct 2018 → Oct 2020 | diabetes mellitus, intermediate coronary syndrome | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03278444 | Jul 2017 → Jul 2021 | hepatocellular carcinoma | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 3 | NCT03274427 | Jul 2017 → Jul 2021 | hepatocellular carcinoma | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05540184 | Sep 2022 → Sep 2025 | acute kidney injury | Beni-Suef University | Unknown | No outcome recorded |
| Phase 4 | NCT03887013 | Mar 2019 → Oct 2020 | coronary artery disorder, diastolic heart failure | China National Center for Cardiovascular Diseases | Unknown | No outcome recorded |
| Phase 4 | NCT02107144 | Apr 2014 → Mar 2023 | coronary artery disorder | Clinical Hospital Center Zemun | Completed | No outcome recorded |
| Phase 4 | NCT00282360 | Feb 1999 → Oct 2003 | coronary artery disorder, type 2 diabetes mellitus | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase not applicable5 trials · 1 met primary | ||||||
| — | NCT07074834 | Feb 2021 → Sep 2022 | coronary artery disorder | Shiyan City Renmin Hospital | Completed | No outcome recorded |
| — | NCT03504202 | Mar 2019 → Apr 2020 | coronary microvascular disorder | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| — | NCT02826616 | Jul 2016 → Aug 2017 | cardiovascular disorder | Chinese PLA General Hospital | Unknown | Met primary |
| — | NCT04511520 | Jul 2013 → Dec 2016 | paroxysmal atrial fibrillation | National Research Center for Preventive Medicine | Completed | No outcome recorded |
| — | NCT01857921 | Dec 2010 → Apr 2018 | coronary artery disorder | Yonsei University | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT03333499 Comparator | Nov 2017 → Dec 2018 | heart failure | Dalian University | Unknown | No outcome recorded |
| Phase 1/2 | NCT06459193 Comparator | Jun 2024 → Jan 2025 | chemotherapy-induced neuropathy | Minia University | Completed | No outcome recorded |
| Phase 2 | NCT01696370 Comparator | Apr 2012 → Apr 2014 | hypertrophic cardiomyopathy | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT06656442 Comparator | Sep 2024 → Feb 2025 | ischemic stroke | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05633563 Comparator | Oct 2021 → Jun 2023 | mitochondrial disease, wild type ATTR amyloidosis | Steen Hvitfeldt Poulsen | Completed | No outcome recorded |
| Phase 4 | NCT04661709 Background | Mar 2021 → Mar 2023 | intermediate coronary syndrome | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03809273 Comparator | Aug 2019 → Dec 2020 | — | Shenyang Northern Hospital | Completed | Met primary |
| Phase 4 | NCT03072082 Background | Jun 2017 → Dec 2018 | coronary artery disorder | Jun Li | Unknown | No outcome recorded |
| — | NCT04702906 Comparator | Feb → Jun 2021 | poisoning | Tanta University | Unknown | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimetazidine | “4. Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid” NCT04980716 ↗ |
| Known as | Dilatan | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | metacardia | “trimetazidine hydrochloride "metacardia" ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)” NCT04702906 ↗ |
| Known as | NSC-759317 | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | TMZ | “Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI” NCT02107144 ↗2“This prospective study aimed to determine whether trimetazidine (TMZ) alters the pharmacodynamic (PD) effects of clopidogrel.” PMID 31292901 ↗ Jul 2019 “Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain.” NCT05633563 ↗ |
| Known as | Trimetazidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Trimetazidine di-hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Trimetazidine dihydrochloride | “The trimetazidine group will receive conventional standard treatment plus Trimetazidine dihydrochloride "metacardia" ® (20 mg three times daily produced by Pharco-Egypt) will...” NCT04702906 ↗ |
| Known as | Trimetazidine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Trimetazidine hydrochloride | “trimetazidine hydrochloride "metacardia" ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)” NCT04702906 ↗2“Trimetazidine hydrochloride may play an anti-tumor role by inhibiting fatty acid oxidation.” NCT03274427 ↗ |
| Known as | Trimethazidine dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Known as | Vastarel | “Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain.” NCT05633563 ↗ |
| Known as | Vastarel MR 35 mg | “When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours...” NCT03715582 ↗ |
| Known as | Vastarel mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL203266 ↗ |
| Action | Inhibit | “free fatty acid inhibition with Trimetazidine” NCT00282360 ↗ |
| Modality | Small molecule | “Trimetazidine is a piperazine derivative.” NCT05147194 ↗ |
| Route | Oral | “oral therapy with trimetazidine” PMID 30725091 ↗ Mar 2019 |